Desentum Oy
🇫🇮Finland
- Country
- 🇫🇮Finland
- Ownership
- Holding
- Established
- 2011-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.desentum.fi
Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants
Phase 1
Completed
- Conditions
- Birch Pollen Allergy
- Interventions
- Biological: Placebo to Match DM-101PXBiological: DM-101PX
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Desentum Oy
- Target Recruit Count
- 30
- Registration Number
- NCT06037148
- Locations
- 🇨🇦
Cliantha Research, Mississauga, Ontario, Canada
Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy
Phase 1
Completed
- Conditions
- Birch Pollen Allergy
- Interventions
- Biological: Placebo to match DM-101Biological: DM-101
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Desentum Oy
- Target Recruit Count
- 27
- Registration Number
- NCT04266028
- Locations
- 🇫🇮
Clinical Research Services Turku, Turku, Finland
© Copyright 2025. All Rights Reserved by MedPath